Shengjing Capsule Improves Spermatogenesis through Upregulating Integrin α6β1 in the NOA Rats

Abstract EN

Objective.

To evaluate the therapeutic effect of Shengjing capsules on nonobstructive azoospermia (NOA) in the rat model.

Methods.

Twenty-five male Sprague–Dawley rats were randomly divided into five groups as follows (n=5 per group): normal group, NOA group, and three Shengjing capsule treatment groups (low-dose, medium-dose, and high-dose groups, respectively).

HE staining and semen smear were performed to assess sperm quality.

The expression levels of PI3K/AKT and integrin α6/β1 were measured by qRT-PCR and western blot analyses.

Results.

In the NOA group, almost all of the seminiferous tubules were vacuolated with a thin layer of basal compartment containing some spermatogonial stem cells.

The counts of sperms in the NOA group were strongly lower than those of the normal group (P=0.0001).

The expression of PI3K/AKT and integrin α6/β1 was scarcely expressed in the NOA group.

All indexes mentioned above were significantly different from those of the medium- and high-dose groups (P=0.001, all).

The sperm count of rats treated with Shengjing capsules was significantly higher than that of the NOA group (P=0.0001).

The rats of Shengjing capsule groups had more layers of spermatogonial stem cells and spermatocytes, and some had intracavitary sperms.

Conclusions.

Shengjing capsules may be a promising therapeutic medicine for NOA.

The underlying mechanisms might involve activating SSCs by upregulating the integrin α6/β1 expression via the PI3K/AKT pathway.